TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02323087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLEXICULT™ SSI-Urinary Kit
Description: Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ID FlexicultTM
Description: Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
Study: NCT03034018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: 10-20 mg taken at bedtime for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken at bedtime for four weeks
Study: NCT01194284

Intervention type: DRUG
Intervention: Mifamurtide
Description: Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
Study: NCT03293329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm manual therapy techniques
Description: 3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm mobilization through active hipopressive gymnastic exercise
Description: Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic compression techniques in shoulder myofascial trigger points
Description: Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
Study: NCT01939483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02608697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03269721

Intervention type: BEHAVIORAL
Intervention: Symptom Questionnaire Measures
Description: M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire

Intervention type: PROCEDURE
Intervention: Brain MRI
Description: Primary neuroimaging outcomes of interest are white matter structural integrity

Intervention type: PROCEDURE
Intervention: Brain MRI
Description: Primary neuroimaging outcomes of interest are white matter structural integrity

Intervention type: PROCEDURE
Intervention: Brain MRI
Description: Primary neuroimaging outcomes of interest are white matter structural integrity
Study: NCT02387957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Study: NCT02669836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression
Description: Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural Augmentation
Description: The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
Study: NCT02552238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
Study: NCT02542644

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrahigh resolution Spectral Domain OCT
Description: The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
Study: NCT03472222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arsha Vidya program
Description: Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
Study: NCT00666432

Intervention type: OTHER
Intervention: This is an observational study model that is family based
Description: This is an observational study model that is family based

Intervention type: OTHER
Intervention: This is an observational study model that is family based
Description: This is an observational study model that is family based

Intervention type: OTHER
Intervention: This is an observational study model that is family based
Description: This is an observational study model that is family based
Study: NCT02036645

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MEDI1814 for IV injection
Description: Monoclonal antibody for IV Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1814 for IV injection
Description: Monoclonal antibody for IV Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1814 for Subcutaneous Injection
Description: Monoclonal antibody for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Placebo for IV injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Subcutaneous Injection
Description: Subcutaneous Placebo Injection
Study: NCT04341961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: Drinking 8 oz of pomegranate juice daily for 2 weeks.
Study: NCT01633125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group music therapy
Description: The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Group music therapy
Description: The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
Study: NCT03842839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Inhalation Powder [Spiriva] 0.018mg
Description: Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Inhalation Powder [Spiriva] 0.018mg
Description: Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol sulphate aerosol (Ventolin) 0.01mg
Description: As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate aerosol (Ventolin) 0.01mg
Description: As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate aerosol (Ventolin) 0.01mg
Description: As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
Study: NCT03265106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BinD19
Description: Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
Study: NCT01448694

Intervention type: OTHER
Intervention: No treatment
Description: No treatment, only collecting observational data.
Study: NCT04318158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: single shot US guided TAP block using 20 ml bupivacaine 0.25%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
Study: NCT00160420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 5mg Tablet, oral Daily for 12 months
Study: NCT00765310

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: R-alpha lipoic acid
Description: 600 mg in morning on empty stomach (two 300 mg capsules)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two capsules once daily in morning on empty stomach
Study: NCT00824980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP10.C8
Description: IP10.C8 Gel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IP10.C8
Description: IP10.C8 Gel 1%
Study: NCT02978443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
Study: NCT01472874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once a day Trientine
Description: Trientine at a dosage of \~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
Study: NCT02536638

Intervention type: OTHER
Intervention: Exposure to pyelonephritis
Description: Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
Study: NCT01092481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
Study: NCT02936050

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diagnostic ultrasound
Description: All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
Study: NCT03551314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intermittent Positive Pressure
Description: - NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: - CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle).
Study: NCT00853502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone cypionate
Description: dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
Study: NCT03877965

Intervention type: DRUG
Intervention: Digoxin
Description: Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
Study: NCT03562065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~* 1.10\^6 CSM / kg~* 2.10\^6 CSM / kg~* 4.10\^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion
Study: NCT00117156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT03371641

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASQ parental questionnaire
Description: ASQ parental questionnaire

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASQ parental questionnaire
Description: ASQ parental questionnaire

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Development scales
Description: WPPSI - IV and NEPSY development scales

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Development scales
Description: WPPSI - IV and NEPSY development scales

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Scale of Conners
Description: Scale of Conners

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Scale of Conners
Description: Scale of Conners

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCQ Questionnaire
Description: SCQ questionnaire

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCQ Questionnaire
Description: SCQ questionnaire

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample (mother)
Description: Blood sample (mother) before delivery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample (mother)
Description: Blood sample (mother) before delivery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord blood sample
Description: Cord blood sample after delivery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord blood sample
Description: Cord blood sample after delivery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placenta sample
Description: Placenta sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placenta sample
Description: Placenta sample
Study: NCT01987817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR101 powder provided in capsules
Description: Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder provided in capsules
Description: Study product formulated to contain only inactive ingredients for use as defined in the protocol
Study: NCT01908829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron 25 mg
Description: Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg
Description: Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg
Description: Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 5 mg
Description: Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 10 mg
Description: Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 25 mg matching placebo
Description: Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 25 mg matching placebo
Description: Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 50 mg matching placebo
Description: Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 50 mg matching placebo
Description: Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 5 mg matching placebo
Description: Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin 10 mg matching placebo
Description: Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin 10 mg matching placebo
Description: Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Study: NCT04247997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: disconnect pulmonary vague nerve branches
Description: When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
Study: NCT03054038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Given by mouth

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03571737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Patch 4%
Description: Lidocaine patch
Study: NCT03299764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pursed lip breathing ventilation
Description: A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-invasive ventilation
Description: Standard non-invasive ventilation